Literature DB >> 10938483

The role of cardiovascular magnetic resonance in heart failure.

K Rajappan1, N G Bellenger, L Anderson, D J Pennell.   

Abstract

Cardiovascular Magnetic Resonance (CMR) is an accepted gold standard for non-invasive, accurate, and reproducible assessment of cardiac mass and function. The interest in its use for viability, myocardial perfusion and coronary artery imaging is also widespread and growing rapidly as the hardware and expertise becomes available in more centres, and the scans themselves become more cost effective. In patients with heart failure, accurate and reproducible serial assessment of remodelling is of prognostic importance and the lack of exposure to ionizing radiation is helpful. The concept of an integrated approach to heart failure and its complications using CMR is fast becoming a reality, and this will be tested widely in the coming few years, with the new generation of dedicated CMR scanners.

Entities:  

Mesh:

Year:  2000        PMID: 10938483     DOI: 10.1016/s1388-9842(00)00096-9

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  9 in total

1.  Correlation between clinical presentation and delayed-enhancement MRI pattern in myocarditis.

Authors:  L Natale; A De Vita; C Baldari; A Meduri; M Pieroni; A Lombardo; F Crea; L Bonomo
Journal:  Radiol Med       Date:  2012-02-10       Impact factor: 3.469

Review 2.  Positron emission tomography and magnetic resonance imaging in heart failure.

Authors:  Frank M Bengel
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

3.  The prognostic value of right ventricular long axis strain in non-ischaemic dilated cardiomyopathies using standard cardiac magnetic resonance imaging.

Authors:  Nisha Arenja; Johannes H Riffel; Manuel Halder; Charly N Djiokou; Thomas Fritz; Florian Andre; Fabian Aus dem Siepen; Thomas Zelniker; Benjamin Meder; Elham Kayvanpour; Grigorios Korosoglou; Hugo A Katus; Sebastian J Buss
Journal:  Eur Radiol       Date:  2017-02-10       Impact factor: 5.315

Review 4.  The emerging role of MRI in the diagnosis and management of cardiomyopathies.

Authors:  Carlos Eduardo Rochitte; Eduardo Marinho Tassi; Afonso Akio Shiozaki
Journal:  Curr Cardiol Rep       Date:  2006-02       Impact factor: 2.931

5.  Assessment of cardiac remodeling in asymptomatic mitral regurgitation for surgery timing: a comparative study of echocardiography and magnetic resonance imaging.

Authors:  Oner Ozdogan; Alper Yuksel; Cemil Gurgun; Meral Kayikcioglu; Oguz Yavuzgil; Cahide S Cinar
Journal:  Cardiovasc Ultrasound       Date:  2010-08-13       Impact factor: 2.062

6.  Association of cardiovascular disease risk factors with left ventricular mass, biventricular function, and the presence of silent myocardial infarction on cardiac MRI in an asymptomatic population.

Authors:  Eliel Nham; Sung Mok Kim; Sang-Chol Lee; Sung-A Chang; Jidong Sung; Soo Jin Cho; Shin Yi Jang; Yeon Hyeon Choe
Journal:  Int J Cardiovasc Imaging       Date:  2016-05-21       Impact factor: 2.357

7.  Quantitative evaluation of ischemic myocardial scar tissue by unenhanced T1 mapping using 3.0 Tesla MR scanner.

Authors:  Aylin Okur; Mecit Kantarcı; Yeşim Kızrak; Sema Yıldız; Berhan Pirimoğlu; Leyla Karaca; Hayri Oğul; Serdar Sevimli
Journal:  Diagn Interv Radiol       Date:  2014 Sep-Oct       Impact factor: 2.630

8.  Assessment of right ventricular function using cardiovascular magnetic resonance in patients with type 2 diabetes mellitus.

Authors:  Yongning Shang; Yulin Zhang; Weiling Leng; Xiaotian Lei; Liu Chen; Xiaoyue Zhou; Ziwen Liang; Jian Wang
Journal:  Quant Imaging Med Surg       Date:  2022-02

9.  Prognostic implications of late gadolinium enhancement at the right ventricular insertion point in patients with non-ischemic dilated cardiomyopathy: A multicenter retrospective cohort study.

Authors:  Jeong-Eun Yi; Junbeom Park; Hye-Jeong Lee; Dong Geum Shin; Yookyung Kim; Minsuk Kim; Kihwan Kwon; Wook Bum Pyun; Young Jin Kim; Boyoung Joung
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.